OriCiro Genomics, a Tokyo, Japan-based developer of cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, closed its Series B2 financing of undisclosed amount.
Asahi Kasei Medical Co., Ltd. made the investment.
Through this investment, the company intends to accelerate growth by leveraging expected synergies between both companies in the healthcare area.
OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene and cell-based therapies and synthetic biology. Its tool is used for research, development and manufacturing in multiple industries including pharmaceutical, diagnostics, agriculture and food sectors.
FinSMEs
16/06/2022